# Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)

> **NCT03613857** · — · COMPLETED · sponsor: **Cairo University** · enrollment: 1022 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** Ticagrelor 90mg

## Key facts

- **NCT ID:** NCT03613857
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-15
- **Primary completion:** 2018-07-28
- **Final completion:** 2018-07-28
- **Target enrollment:** 1022 (ACTUAL)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03613857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03613857, "Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03613857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*